Xvivo Perfusion AB (publ)

OM:XVIVO Rapporto sulle azioni

Cap. di mercato: SEK 14.1b

Xvivo Perfusion Gestione

Gestione criteri di controllo 3/4

Xvivo Perfusion Il CEO è Christoffer Rosenblad, nominato in Jan2022, ha un mandato di 2.83 anni. possiede direttamente 0.18% delle azioni della società, per un valore di SEK 24.92M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4.1 anni.

Informazioni chiave

Christoffer Rosenblad

Amministratore delegato

SEK 5.0m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO2.8yrs
Proprietà del CEO0.2%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27
Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Oct 25
With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

AMMINISTRATORE DELEGATO

Christoffer Rosenblad (49 yo)

2.8yrs

Mandato

SEK 5,031,000

Compensazione

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Christoffer Rosenblad
Chief Executive Officer2.8yrsSEK 5.03m0.18%
SEK 24.9m
Kristoffer Nordstrom
Chief Financial Officer4yrsNessun dato0.0085%
SEK 1.2m
Lena Hagman
Chief Operating Officer1.9yrsNessun dato0.0063%
SEK 896.1k
Johan Holmstrom
Senior Vice President of Commercial EMEAless than a yearNessun dato0.012%
SEK 1.7m
Ylva Vihoj
Global Human Resources Director1.8yrsNessun datoNessun dato
Magnus Nilsson
Senior Advisor4.4yrsSEK 1.62mNessun dato
Andreas Wallinder
Chief Medical Officer4.2yrsNessun dato0.011%
SEK 1.5m
Mark Reade
Senior Vice President of North Americaless than a yearNessun datoNessun dato

2.4yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di XVIVO è considerato esperto (durata media dell'incarico 2.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Gosta Johannesson
Chairman of the Board11.8yrsSEK 440.00k0.015%
SEK 2.1m
Lars Henriksson
Independent Director4.1yrsNessun dato0.0076%
SEK 1.1m
Erik Stromqvist
Independent Director1.6yrsNessun dato0.18%
SEK 24.9m
Camilla Oberg
Independent Director8.5yrsSEK 130.00k0.0034%
SEK 482.6k
Lena Hoglund
Independent Director4.1yrsNessun dato0.0041%
SEK 582.8k
Goran Dellgren
Independent Director2.6yrsNessun datoNessun dato

4.1yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di XVIVO sono considerati esperti (durata media dell'incarico 4.1 anni).